<DOC>
	<DOCNO>NCT02660944</DOCNO>
	<brief_summary>This study evaluate impact 13 bi-weekly intravenous infusion RSLV-132 cutaneous manifestation subject systemic lupus erythematosus .</brief_summary>
	<brief_title>A Phase 2a RSLV-132 Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>CLASI score great equal 10 Baseline Positive one RNA autoantibodies 1. severe , active central nervous system ( CNS ) involvement Screening ; 2. severe renal involvement Screening ( urine protein/creatinine ratio &gt; 200 mg/mmol , estimate creatinine clearance &lt; 30 mL/min ) ; 3. use cyclophosphamide within 3 month Baseline visit ; 4. use rituximab within 6 month Baseline visit ; 5. use belimumab within 3 month Baseline visit ; 6. use background medication within 1 month Baseline excess : i. mycophenolate mofetil &gt; 3 g/day ; ii . azathioprine &gt; 200 mg/day ; iii . methotrexate &gt; 25 mg/day ; iv . hydroxychloroquine &gt; 400 mg/day ; v. prednisone ( equivalent ) &gt; 15 mg/day ; 7. use intravenous steroid `` pulse '' within 2 month Baseline ; 8. use intramuscular steroid injection within 1 month Baseline ; 9. change SLE medication within 1 month Baseline ; 10. presence clinically significant infection judgement Investigator within seven day prior receipt first dose study drug ; 11. positive viral load test hepatitis B , C , HIV Screening ; 12. participation another clinical trial receipt investigational product within 3 month 5 half life , last administration ( whichever longer ) Baseline ; 13. positive pregnancy test Screening Baseline ; 14. female subject currently breast feed Baseline ; 15. inability unwillingness comply protocolspecified procedure , opinion Investigator , would make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>